Johnson & Johnson (JNJ) Q4 FY25 earnings call

Johnson & Johnson concluded a strong FY25, exceeding financial expectations and setting the stage for accelerated growth in 2026, with a clear path to double-digit growth by the decade's end. Fueled by a robust pipeline and strategic portfolio shifts, the company is leveraging its depth in Innovative Medicine and MedTech to drive sustainable growth, despite ongoing STELARA erosion and increased tariff impacts. Management remains confident in its ability to deliver value through innovation and disciplined capital allocation.